The two COVID-19 vaccines that recently received emergency approval from the US and other worldwide regulatory agencies are expected to pose little risk to the rare disease community, including to patients with compromised immune systems or those participating in gene therapy studies.
Read moreCOVID-19 Vaccines Pose Little Risk to Rare Disease Patients, FDA, CDC Say
